{"mainPropery":{"diseaseId":3460,"diseaseName":"Hereditary melanoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/3460/hereditary-melanoma","synonyms":["Hereditary Cutaneous Melanoma","Familial Cutaneous Melanoma","Hereditary Cutaneous (Skin) Melanoma","Familial Melanoma"],"synonyms-with-source":[{"name":"Hereditary Cutaneous Melanoma","source":"NCI Thesaurus"},{"name":"Familial Cutaneous Melanoma","source":"NCI thesaurus"},{"name":"Hereditary Cutaneous (Skin) Melanoma","source":"NCI Thesaurus"},{"name":"Familial Melanoma","source":"NCI Thesaurus"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"618"},{"identifierType":"NCI Thesaurus","identifierId":"C8498"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":4293,"resourceName":"Melanoma Research Alliance","abbreviation":"MRA","address1":"730 15th Street, NW","address2":"","address3":"","address4":"","address5":"","city":"Washington","state":"DC","zip":"20005","country":"United States","phone":"+1-202-336-8935","tty":"","tollFree":"","fax":"","email":" info@curemelanoma.org","url":"https://www.curemelanoma.org/","freeText":""}],"resource descriptions":[{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=618' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:155600' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/melanoma' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2161,"resourceId":3369,"resourceName":"HealthWell Foundation","descriptionText":"The <a href='http://www.healthwellfoundation.org/melanoma' target='_blank'>HealthWell Foundation</a> provides financial assistance for underinsured patients living with chronic and life-altering conditions. They offer help with drug copayments, deductibles, and health insurance premiums for patients with specific diseases. The disease fund status can change over time, so you may need to check back if funds are not currently available.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2162,"resourceId":3371,"resourceName":"The Assistance Fund","descriptionText":"<a href='https://tafcares.org/patients/covered-diseases/' target='_blank'>The Assistance Fund</a> provides various services, including education and financial aid, to help patients with a chronic or serious illness cover the cost of FDA-approved medications. Patients must be U.S citizens or permanent residents.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":7951,"phenoTypeName":"Melanoma","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":7349,"phenoTypeName":"Nevus","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":4755,"phenoTypeName":"Abnormal hair morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":1837,"phenoTypeName":"Abnormality of the lymphatic system","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10279,"phenoTypeName":"Dry skin","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4064,"phenoTypeName":"Freckling","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13705,"phenoTypeName":"Abnormality of extrapyramidal motor function","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11455,"phenoTypeName":"Neoplasm of the breast","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4303,"phenoTypeName":"Neoplasm of the pancreas","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":108,"phenoTypeName":"Neoplasm of the stomach","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":10492,"phenoTypeName":"Retinopathy","frequencyText":"Occasional","percentRanges":"5%-29%"}],"medicalProducts":[{"productId":727,"genericName":"Encorafenib + binimetinib","tradeName":"Braftovi + Mektovi","tradeLink":"https://www.braftovimektovi.com/hcp/","manufacturer":"","sponsor":"Array BioPharma, Inc.","indication":"June 2018, approved in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","drugInformationLink":"","medlinePlusLink":""},{"productId":608,"genericName":"Pembrolizumab","tradeName":"Keytruda","tradeLink":"https://www.keytruda.com/melanoma/","manufacturer":"","sponsor":"Merck, Sharp & Dohme Corp","indication":"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=KEYTRUDA","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614048.html"},{"productId":575,"genericName":"Trametinib","tradeName":"Mekinist","tradeLink":"http://www.mekinist.com/","manufacturer":"","sponsor":"GlaxoSmithKline, LLC","indication":"Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.","drugInformationLink":"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aeaf0430-f8ad-4e72-9dbf-1954503c3410","medlinePlusLink":""},{"productId":720,"genericName":"Trametinib and dabrafenib combination","tradeName":"Mekinist And Tafinlar","tradeLink":"https://www.us.tafinlarmekinist.com/","manufacturer":"","sponsor":"Novartis Pharmaceuticals Corporation","indication":"April 2018 approved combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.","drugInformationLink":"","medlinePlusLink":""},{"productId":708,"genericName":"Nivolumab","tradeName":"Opdivo","tradeLink":"https://www.opdivo.com/metastatic-melanoma/","manufacturer":"","sponsor":"Bristol-Myers Squibb Co","indication":"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. And treatment of patients with melanoma with involvement of lymph nodes or metestatic disease who have undergone complete resection.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/opdivo","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614056.html"},{"productId":121,"genericName":"Aldesleukin","tradeName":"Proleukin","tradeLink":"https://www.proleukin.com/","manufacturer":"","sponsor":"Chiron Corporation","indication":"Treatment of adults with metastatic melanoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/Proleukin","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a692009.html"},{"productId":532,"genericName":"Peginterferon Alfa-2b","tradeName":"Sylatron","tradeLink":"http://www.pegintron.com/index.html","manufacturer":"Schering/Merck","sponsor":"Schering-Plough Corporation","indication":"Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy ","drugInformationLink":"http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=41497","medlinePlusLink":""},{"productId":576,"genericName":"Dabrafenib","tradeName":"Tafinlar","tradeLink":"http://www.tafinlar.com/","manufacturer":"","sponsor":"GlaxoSmithKline, LLC","indication":"Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.  ","drugInformationLink":"http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=803beaaa-33f9-48cc-9a95-c2e887e095b4","medlinePlusLink":""},{"productId":551,"genericName":"Technetium Tc99m sulfur colloid injection, lyophilized","tradeName":"Technetium Tc99m Sulfur Colloi","tradeLink":"http://www.pharmalucence.com/section.php?sec=54&prod=195","manufacturer":"","sponsor":"Pharmalucence, Inc.","indication":"Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter ","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Technetium Tc 99m Sulfur Colloid","medlinePlusLink":""},{"productId":533,"genericName":"Ipilimumab","tradeName":"Yervoy","tradeLink":"https://www.yervoy.com/","manufacturer":"","sponsor":"Bristol-Myers Squibb Pharmaceutical","indication":"Treatment of unresectable or metastatic melanoma for patients 12 years old and up.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/yervoy","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a611023.html"}],"EncodedName":"Hereditary_melanoma"}